p38MAPK: stress responses from molecular mechanisms to therapeutics
- 31 August 2009
- journal article
- review article
- Published by Elsevier BV in Trends in Molecular Medicine
- Vol. 15 (8), 369-379
- https://doi.org/10.1016/j.molmed.2009.06.005
Abstract
No abstract availableKeywords
This publication has 127 references indexed in Scilit:
- MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targetsClinical Science, 2008
- Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: A MLK-3-MKK7-dependent mechanismCellular Signalling, 2008
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- MK2 controls the level of negative feedback in the NF-κB pathway and is essential for vascular permeability and airway inflammationThe Journal of Experimental Medicine, 2007
- Differential regulation and properties of MAPKsOncogene, 2007
- A CD36-dependent signaling cascade is necessary for macrophage foam cell formationCell Metabolism, 2006
- Tumor Necrosis Factor-induced Toxic Liver Injury Results from JNK2-dependent Activation of Caspase-8 and the Mitochondrial Death PathwayOnline Journal of Public Health Informatics, 2006
- p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseasesNature Reviews Drug Discovery, 2003
- Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinomaCancer, 2003
- The Hallmarks of CancerCell, 2000